| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
Co-treating LPS (1 μg/mL) with ATP (5 mM) for one hour has a positive impact on HGFs' NLRP3 inflammasome activation [3]. IL-1β, KC, and MIP-2 are all required for the caspase-1 activation-dependent induction of BMDM mortality by ATP (2 mM; 0.5-24 hours) [4]. In vitro, ATP stimulates neutrophil chemotaxis [4].
|
|---|---|
| ln Vivo |
ATP (50 mg/kg; ip) protects the outer shell against infecting bacteria [4]. ATP covers IL-1β, KC and MIP-2 in the periphery as well as neutrophil recruitment [4].
|
| Animal Protocol |
Animal/Disease Models: Fourweeks old Kunming mice (18-22 g) [4]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection before bacterial (E. coli) challenge Experimental Results: Protect mice from bacterial infection. |
| References |
[1]. Swennen EL, et al. Immunoregulatory effects of adenosine 5'-triphosphate on cytokine release from stimulated whole blood. Eur J Immunol. 2005 Mar;35(3):852-8.
[2]. M J L Bours, et al. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006 Nov;112(2):358-404. [3]. Shuo Xu, et al. Doxycycline inhibits NAcht Leucine-rich repeat Protein 3 inflammasome activation and interleukin-1β production induced by Porphyromonas gingivalis-lipopolysaccharide and adenosine triphosphate in human gingival fibroblasts. Arch Oral Biol. 2019 Nov;107:104514. [4]. Yang Xiang, et al. Adenosine-5'-Triphosphate (ATP) Protects Mice against Bacterial Infection by Activation of the NLRP3 Inflammasome. PLoS One. 2013; 8(5): e63759. |
| Molecular Formula |
C10H16N5O13P3
|
|---|---|
| Molecular Weight |
507.1810
|
| CAS # |
56-65-5
|
| Related CAS # |
ATP disodium salt;987-65-5;ATP disodium trihydrate;51963-61-2;ATP dimagnesium;74804-12-9;ATP-13C10,15N5 disodium;ATP disodium salt hydrate;34369-07-8;ATP dipotassium;42373-41-1;ATP ditromethamine;102047-34-7;ATP-13C10,15N5;752972-20-6
|
| SMILES |
P(=O)(O[H])(OP(=O)(O[H])OP(=O)(O[H])O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3=C(N([H])[H])N=C([H])N=C23)O1)O[H])O[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~197.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (197.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9717 mL | 9.8584 mL | 19.7169 mL | |
| 5 mM | 0.3943 mL | 1.9717 mL | 3.9434 mL | |
| 10 mM | 0.1972 mL | 0.9858 mL | 1.9717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02580253 | Withdrawn | Drug: Individualized Chemotherapy Drug: mFOLFOX6 |
Hepatocellular Carcinoma | Zhejiang University | November 1, 2017 | Phase 2 |
| NCT00014248 | Completed | Drug: adenosine triphosphate Procedure: quality-of-life assessment |
Cachexia Unspecified Adult Solid Tumor, Protocol Specific |
Dartmouth-Hitchcock Medical Center | October 2000 | Phase 1 |
| NCT00565188 | Completed | Drug: Adenosine 5'-triphosphate | Cancer Palliative Care |
Maastricht University Medical Center | March 2002 | Phase 3 |
| NCT02279511 | Completed | Drug: ADENOSINE TRIPHOSPHATE Drug: PLACEBO |
Alzheimer's Disease | Sara Varea | December 2014 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA